Cargando…
A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report
BACKGROUND: Lung cancer is a malignant tumor with high morbidity and mortality worldwide. At present, the main treatment methods for patients with advanced non-small cell lung cancer (NSCLC) include molecular targeted therapy and immunotherapy. The efficacy rate of immune checkpoint inhibitor (ICI)...
Autores principales: | Xu, Fangye, Xiao, Chunmei, Sun, Weijie, He, Yuange, Chalela, Roberto, Masuda, Ken, Ulivi, Paola, Shen, Kai, Shao, Qianwen, Xu, Jiali, Liu, Lianke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469170/ https://www.ncbi.nlm.nih.gov/pubmed/36111030 http://dx.doi.org/10.21037/atm-22-3582 |
Ejemplares similares
-
Chest wall trauma leading to a metallic foreign body in the right subclavian vein: a case report
por: Chen, Anping, et al.
Publicado: (2021) -
Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report
por: Du, Wenxing, et al.
Publicado: (2020) -
Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report
por: Liang, Lubiao, et al.
Publicado: (2022) -
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022) -
Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
por: Song, Yang, et al.
Publicado: (2020)